Sprint Bioscience development requires well-functioning partnerships with universities and individual researchers. We always strive to connect with the very best skills available.
Sprint Bioscience owns all results and rights to our research.
Dr Ravi Amaravadi
In the autumn of 2014 we began a collaboration with Dr. Ravi Amaravadi, one of the key figures of autophagy research. Dr. Ravi Amaravadi is scientific adviser for our work on the Vps34 project. He works at the University of Pennsylvania as one of the leaders of the Cancer Therapeutics Program at the Abramson Cancer Center, and was elected in 2015 to the American Society of Clinical Investigation. He conducts both clinical and translational research with a focus on autophagy inhibition as cancer treatment.
Professor Dan Grandér
In April 2015 Sprint Bioscience signed a collaboration agreement with Professor Dan Grandér at the Department of Oncology-Pathology, Karolinska Insitute. Professor Grandér’s research group work on mechanisms of drug resistance in tumors. Together we will deepen our knowledge of how autophagy results in resistance. This will be used to strengthen the Sprint Bioscience project Vps34 that aims to inhibit autophagy in cancer cells.
Professor Pär Nordlund
Professor Pär Nordlund at the Department of Oncology-Pathology, Karolinska Institute is one of the co founders of Sprint Bioscience. Sprint Bioscience uses several technologies that have been developed or refined in Pär Nordlund’s group, mainly in the area of different technologies used in biophysics and structural biochemistry.
Dr. Bassam Janji
In January 2017 Sprint Bioscience entered into a research collaboration with Associate Head of Laboratory Bassam Janji at the Department of Oncology, Luxembourg Institute of Health. Dr. Janji’s pioneering research has pointed out autophagy as a key mechanism involved in tumor escape from the immune system. In a joint effort, and using Sprint Bioscience autophagy inhibitors, we investigate cancer immunotherapy and develop anti-cancer drugs that improve tumors susceptibility to immune cell-mediated killing.